Clinical Trial Update: A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma. [Phase 2, Phase 3]

View source ↗

Summary

A multicenter prospective diagnostic study is evaluating 68Ga-BCMA PET/CT to target BCMA expression in multiple myeloma. The Phase 2/3 trial is currently not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 68Ga-BCMA PET/CT (68Ga-BCMA PET imaging agent)

Snippet

Sponsor: Peking University First Hospital | Conditions: Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING